| DNA replication |
1.85 |
5.95e-2 |
34/36 (94.44%) |
PCNA;MCM5;FEN1;...
|
| Graft-versus-host disease |
1.79 |
7.93e-2 |
32/42 (76.19%) |
GZMB;HLA-DQB1;PRF1;...
|
| Base excision repair |
1.75 |
9.26e-2 |
29/33 (87.88%) |
PCNA;FEN1;POLE2;...
|
| Type I diabetes mellitus |
1.73 |
7.44e-2 |
38/43 (88.37%) |
GZMB;CPE;HLA-DQB1;...
|
| Allograft rejection |
1.71 |
7.93e-2 |
32/38 (84.21%) |
GZMB;HLA-DQB1;PRF1;...
|
| Autoimmune thyroid disease |
1.53 |
3.85e-1 |
46/53 (86.79%) |
GZMB;HLA-DQB1;PRF1;...
|
| Antigen processing and presentation |
1.48 |
4.29e-1 |
60/78 (76.92%) |
CTSB;CTSL;HLA-DQB1;...
|
| Systemic lupus erythematosus |
1.47 |
4.02e-1 |
45/135 (33.33%) |
C2;ACTN1;SNRPB;...
|
| N-Glycan biosynthesis |
1.47 |
3.84e-1 |
38/50 (76%) |
MAN2A1;ALG8;MOGS;...
|
| Cell cycle |
1.43 |
4.62e-1 |
110/124 (88.71%) |
PCNA;MCM5;E2F2;...
|
| Pyrimidine metabolism |
1.43 |
4.35e-1 |
40/56 (71.43%) |
TYMS;DTYMK;CDA;...
|
| Cholesterol metabolism |
1.39 |
4.46e-1 |
44/50 (88%) |
APOA1;VDAC1;APOA2;...
|
| Epstein-Barr virus infection |
1.39 |
4.21e-1 |
189/202 (93.56%) |
CXCL10;RELB;HES1;...
|
| Viral carcinogenesis |
1.39 |
4.01e-1 |
149/203 (73.4%) |
DNAJA3;BAD;ACTN1;...
|
| Various types of N-glycan biosynthesis |
1.37 |
4.36e-1 |
26/39 (66.67%) |
MAN2A1;RPN2;DAD1;...
|
| Hepatocellular carcinoma |
1.33 |
4.50e-1 |
135/168 (80.36%) |
FZD5;E2F2;MET;...
|
| Ubiquitin mediated proteolysis |
1.32 |
4.41e-1 |
87/140 (62.14%) |
NEDD4L;SOCS1;MGRN1;...
|
| Intestinal immune network for IgA production |
1.32 |
4.24e-1 |
38/48 (79.17%) |
HLA-DQB1;HLA-DPA1;CD40;...
|
| Primary immunodeficiency |
1.32 |
4.23e-1 |
33/38 (86.84%) |
CD79A;CD40;CD8A;...
|
| Bacterial invasion of epithelial cells |
1.30 |
4.59e-1 |
59/77 (76.62%) |
MET;ACTB;FN1;...
|
| Glycolysis / Gluconeogenesis |
1.30 |
4.45e-1 |
56/67 (83.58%) |
PGK1;PCK1;ALDOA;...
|
| Central carbon metabolism in cancer |
1.30 |
4.35e-1 |
67/70 (95.71%) |
MET;FGFR3;SLC7A5;...
|
| Phagosome |
1.29 |
4.27e-1 |
118/152 (77.63%) |
ACTB;COLEC12;SFTPD;...
|
| Porphyrin and chlorophyll metabolism |
1.28 |
4.58e-1 |
23/43 (53.49%) |
UGT2B28;CP;UGT2B17;...
|
| Glutathione metabolism |
1.28 |
4.53e-1 |
43/57 (75.44%) |
ANPEP;LAP3;GSTA1;...
|
| Viral myocarditis |
1.27 |
4.59e-1 |
53/60 (88.33%) |
ACTB;CAV1;HLA-DQB1;...
|
| Prostate cancer |
1.27 |
4.58e-1 |
93/97 (95.88%) |
PLAT;E2F2;BAD;...
|
| mTOR signaling pathway |
1.23 |
4.67e-1 |
114/154 (74.03%) |
FZD5;SGK1;SLC7A5;...
|
| Pancreatic cancer |
1.22 |
4.58e-1 |
75/76 (98.68%) |
E2F2;BAD;GADD45G;...
|
| Human papillomavirus infection |
1.21 |
4.64e-1 |
284/331 (85.8%) |
FZD5;GNAS;HES1;...
|
| Oxidative phosphorylation |
-0.99 |
7.46e-1 |
93/133 (69.92%) |
ATP5PF;COX6C;ATP5MC3;...
|
| Transcriptional misregulation in cancer |
-0.99 |
7.52e-1 |
158/192 (82.29%) |
AFF1;KMT2A;JMJD1C;...
|
| Synthesis and degradation of ketone bodies |
-1.00 |
7.46e-1 |
9/10 (90%) |
BDH2;ACAT1;HMGCS1
|
| Thyroid cancer |
-1.01 |
7.46e-1 |
36/37 (97.3%) |
LEF1;TCF7L2;TPM3;...
|
| Parathyroid hormone synthesis, secretion and action |
-1.01 |
7.50e-1 |
98/106 (92.45%) |
CDKN1A;ADCY8;CYP24A1;...
|
| Fatty acid degradation |
-1.01 |
7.52e-1 |
40/43 (93.02%) |
HADHB;ACAA2;ACSBG1;...
|
| Mitophagy |
-1.01 |
7.49e-1 |
56/68 (82.35%) |
GABARAPL1;SP1;SQSTM1;...
|
| Coronavirus disease |
-1.03 |
7.49e-1 |
215/232 (92.67%) |
IL1B;RPL26;SELP;...
|
| ECM-receptor interaction |
-1.30 |
6.73e-1 |
80/88 (90.91%) |
ITGA2B;TNXB;COL9A3;...
|
| Phosphonate and phosphinate metabolism |
-1.31 |
6.57e-1 |
5/6 (83.33%) |
CHPT1
|
| Valine, leucine and isoleucine degradation |
-1.32 |
6.48e-1 |
42/48 (87.5%) |
AOX1;DLD;PCCA;...
|
| Lipid and atherosclerosis |
-1.32 |
6.48e-1 |
190/215 (88.37%) |
IL1B;NCF2;BCL2L1;...
|
| Glyoxylate and dicarboxylate metabolism |
-1.33 |
6.41e-1 |
23/30 (76.67%) |
GLUL;DLD;PCCA;...
|
| Selenocompound metabolism |
-1.34 |
6.66e-1 |
11/17 (64.71%) |
CTH;KYAT3;PAPSS2
|
| RNA polymerase |
-1.34 |
7.05e-1 |
23/31 (74.19%) |
POLR2C;POLR2A;POLR3K;...
|
| RNA degradation |
-1.34 |
7.25e-1 |
53/79 (67.09%) |
LSM6;DCP1A;CNOT4;...
|
| Necroptosis |
-1.36 |
6.97e-1 |
113/159 (71.07%) |
STAT2;CAMK2B;SQSTM1;...
|
| GnRH secretion |
-1.36 |
7.48e-1 |
60/64 (93.75%) |
GABBR1;GPER1;PIK3R3;...
|
| Gastric acid secretion |
-1.38 |
6.87e-1 |
63/76 (82.89%) |
CAMK2B;ITPR1;ADCY1;...
|
| Cardiac muscle contraction |
-1.40 |
6.76e-1 |
64/87 (73.56%) |
SLC8A1;MYL2;ASPH;...
|
| Salivary secretion |
-1.41 |
6.71e-1 |
76/93 (81.72%) |
ATP1A3;CST4;ATP1B3;...
|
| IL-17 signaling pathway |
-1.50 |
3.76e-1 |
84/94 (89.36%) |
FADD;IL5;NFKBIA;...
|
| Basal transcription factors |
-1.50 |
4.23e-1 |
37/45 (82.22%) |
TAF7L;GTF2F1;GTF2H1;...
|
| Steroid biosynthesis |
-1.50 |
4.29e-1 |
19/20 (95%) |
DHCR7;HSD17B7;NSDHL;...
|
| Protein digestion and absorption |
-1.53 |
4.03e-1 |
78/103 (75.73%) |
SLC8A1;SLC1A5;COL5A3;...
|
| Apelin signaling pathway |
-1.56 |
3.83e-1 |
117/137 (85.4%) |
GNAI3;PLCB2;SLC8A1;...
|
| Fatty acid elongation |
-1.56 |
4.68e-1 |
19/27 (70.37%) |
HACD1;HADHB;ACAA2;...
|
| Tryptophan metabolism |
-1.65 |
2.92e-1 |
35/42 (83.33%) |
KMO;CYP1A1;ALDH8A1;...
|
| Sulfur metabolism |
-1.68 |
3.12e-1 |
9/10 (90%) |
SELENBP1;SQOR;TST;...
|
| Legionellosis |
-1.69 |
5.94e-1 |
51/57 (89.47%) |
IL1B;NAIP;BNIP3;...
|
